EYZURCI Trademark

Trademark Overview


On Wednesday, June 21, 2023, a trademark application was filed for EYZURCI with the United States Patent and Trademark Office. The USPTO has given the EYZURCI trademark a serial number of 98053336. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Wednesday, January 8, 2025. This trademark is owned by Amgen Inc.. The EYZURCI trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations and substances for use in the treatment of hematological, immune, autoimmune, inflammatory and respiratory diseases and disorders; pharmaceutical preparations and substances for the treatment of cancer and cardiovascular diseases and disorders; pharmaceutical preparations and substances used for the treatment of blood cells and blood vessel diseases and disorders; pharmaceutical preparations and substances for the treatment of oncological, and ophthalmic diseases and disorders; pharmaceutical preparations and substances for the treatment of inflammatory disorders of the central nervous system; pharmaceutical preparations and substances used for the treatment of hemolytic anemia, thrombocytopenia and kidney failure
eyzurci

General Information


Serial Number98053336
Word MarkEYZURCI
Filing DateWednesday, June 21, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateWednesday, January 8, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 28, 2024

Trademark Statements


Goods and Servicespharmaceutical preparations and substances for use in the treatment of hematological, immune, autoimmune, inflammatory and respiratory diseases and disorders; pharmaceutical preparations and substances for the treatment of cancer and cardiovascular diseases and disorders; pharmaceutical preparations and substances used for the treatment of blood cells and blood vessel diseases and disorders; pharmaceutical preparations and substances for the treatment of oncological, and ophthalmic diseases and disorders; pharmaceutical preparations and substances for the treatment of inflammatory disorders of the central nervous system; pharmaceutical preparations and substances used for the treatment of hemolytic anemia, thrombocytopenia and kidney failure

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, June 29, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAmgen Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799

Party NameAmgen Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799

Trademark Events


Event DateEvent Description
Saturday, June 24, 2023NEW APPLICATION ENTERED
Thursday, June 29, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, April 15, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, April 15, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, December 5, 2023ASSIGNED TO EXAMINER
Thursday, December 7, 2023NON-FINAL ACTION WRITTEN
Thursday, December 7, 2023NON-FINAL ACTION E-MAILED
Thursday, December 7, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, December 20, 2023APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Wednesday, December 20, 2023APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Monday, April 15, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 22, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, May 28, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 23, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, May 8, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 28, 2024PUBLISHED FOR OPPOSITION
Wednesday, January 8, 2025SOU TEAS EXTENSION RECEIVED
Wednesday, January 8, 2025SOU EXTENSION 1 FILED
Thursday, January 9, 2025SOU EXTENSION 1 GRANTED
Monday, March 3, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED